Clinical Trial Update: Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating co-infusion of regulatory T cell–enriched donor lymphocytes with a CD3-depleted hematopoietic stem cell graft to preven…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• CD3-depleted hematopoietic stem cell graft (CD3-depleted hematopoietic stem cell graft)
• Treg-enriched donor lymphocytes (regulatory T cell–enriched donor lymphocytes)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk | Phase 2, Phase 3 | Status: RECRUITING